Antenatal Allopurinol During Fetal Hypoxia
Primary Purpose
Fetal Hypoxia, Reperfusion Injury
Status
Unknown status
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Allopurinol sodium
Mannitol
Sponsored by
About this trial
This is an interventional treatment trial for Fetal Hypoxia focused on measuring allopurinol, neuroprotection, reperfusion injury, fetal hypoxia, post hypoxic-ischemic reperfusion damage
Eligibility Criteria
Inclusion Criteria: Gestational age of 36 weeks or more Non-reassuring CTG, significant events on the STAN-monitor AND/OR FBS < 7.20 Exclusion Criteria: Chromosomal abnormalities
Sites / Locations
- AMC
- VUmc
- Gelre hospitals
- Jeroen Bosch Hospital
- Groene Hart Hospital
- UMCG
- LUMC
- Maastricht University Medical Center
- Wilhelmina Children's Hospital/UMC Utrecht
- Diakonessenhuis
- Maxima Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Allopurinol
Placebo
Arm Description
500 mg allopurinol/ 50 mL water for injection intravenously
500 mg mannitol/50 mL water for injection intravenously
Outcomes
Primary Outcome Measures
Free radical production and markers of neuronal damage
Secondary Outcome Measures
Developmental outcome
Mortality
Severe composite morbidity
Full Information
NCT ID
NCT00189007
First Posted
September 11, 2005
Last Updated
March 28, 2012
Sponsor
UMC Utrecht
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
1. Study Identification
Unique Protocol Identification Number
NCT00189007
Brief Title
Antenatal Allopurinol During Fetal Hypoxia
Official Title
Does Antenatal Allopurinol Administration Reduce Post-hypoxic-ischemic Reperfusion Damage During Fetal Hypoxia in the Newborn?
Study Type
Interventional
2. Study Status
Record Verification Date
March 2012
Overall Recruitment Status
Unknown status
Study Start Date
October 2009 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
UMC Utrecht
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A former study (submitted) in 32 severely asphyxiated infants participating in a randomized double blind study, in which early postnatal allopurinol or a placebo (within 4 hours after birth) was administered to reduce free radical formation and consequently reperfusion/reoxygenation injury to the newborn brain, showed an unaltered high mortality and no clinically relevant improvement in morbidity in infants treated with allopurinol. It was hypothesized that postnatal allopurinol treatment started too late to reduce reperfusion-induced free radical surge and that initiating allopurinol treatment of the fetus with (imminent) hypoxia already via the mother during labor will be more effective to reduce free radical-induced post-asphyxial brain damage.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fetal Hypoxia, Reperfusion Injury
Keywords
allopurinol, neuroprotection, reperfusion injury, fetal hypoxia, post hypoxic-ischemic reperfusion damage
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
222 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Allopurinol
Arm Type
Experimental
Arm Description
500 mg allopurinol/ 50 mL water for injection intravenously
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
500 mg mannitol/50 mL water for injection intravenously
Intervention Type
Drug
Intervention Name(s)
Allopurinol sodium
Other Intervention Name(s)
Acepurin
Intervention Description
Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
Intervention Type
Drug
Intervention Name(s)
Mannitol
Intervention Description
Mannitol 500 mg/50 mL water for injection, intravenously, single dose
Primary Outcome Measure Information:
Title
Free radical production and markers of neuronal damage
Time Frame
Up to 24 hours postpartum
Secondary Outcome Measure Information:
Title
Developmental outcome
Time Frame
Up to 5 years of age
Title
Mortality
Time Frame
Up to 28 days postpartum
Title
Severe composite morbidity
Time Frame
Up to 28 days postpartum
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Gestational age of 36 weeks or more
Non-reassuring CTG, significant events on the STAN-monitor AND/OR FBS < 7.20
Exclusion Criteria:
Chromosomal abnormalities
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank van Bel, Prof MD PhD
Organizational Affiliation
Wilhelmina Children's Hospital/UMC Utrecht
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Manon JN Benders, MD, PhD
Organizational Affiliation
UMC Utrecht
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jan B Derks, MD, PhD
Organizational Affiliation
UMC Utrecht
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Joepe J Kaandorp, MD
Organizational Affiliation
UMC Utrecht
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gerard H Visser, MD, PhD
Organizational Affiliation
UMC Utrecht
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ben WJ Mol, MD, PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Carin MA Rademaker, PhD
Organizational Affiliation
Clinical Pharmacy, UMCU
Official's Role
Principal Investigator
Facility Information:
Facility Name
AMC
City
Amsterdam
Country
Netherlands
Facility Name
VUmc
City
Amsterdam
Country
Netherlands
Facility Name
Gelre hospitals
City
Apeldoorn
Country
Netherlands
Facility Name
Jeroen Bosch Hospital
City
Den Bosch
Country
Netherlands
Facility Name
Groene Hart Hospital
City
Gouda
Country
Netherlands
Facility Name
UMCG
City
Groningen
Country
Netherlands
Facility Name
LUMC
City
Leiden
Country
Netherlands
Facility Name
Maastricht University Medical Center
City
Maastricht
Country
Netherlands
Facility Name
Wilhelmina Children's Hospital/UMC Utrecht
City
Utrecht
ZIP/Postal Code
3508AB
Country
Netherlands
Facility Name
Diakonessenhuis
City
Utrecht
Country
Netherlands
Facility Name
Maxima Medical Center
City
Veldhoven
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
20167117
Citation
Kaandorp JJ, Benders MJ, Rademaker CM, Torrance HL, Oudijk MA, de Haan TR, Bloemenkamp KW, Rijken M, van Pampus MG, Bos AF, Porath MM, Oetomo SB, Willekes C, Gavilanes AW, Wouters MG, van Elburg RM, Huisjes AJ, Bakker SC, van Meir CA, von Lindern J, Boon J, de Boer IP, Rijnders RJ, Jacobs CJ, Uiterwaal CS, Mol BW, Visser GH, van Bel F, Derks JB. Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study. BMC Pregnancy Childbirth. 2010 Feb 18;10:8. doi: 10.1186/1471-2393-10-8.
Results Reference
background
PubMed Identifier
30138355
Citation
Klumper J, Kaandorp JJ, Schuit E, Groenendaal F, Koopman-Esseboom C, Mulder EJH, Van Bel F, Benders MJNL, Mol BWJ, van Elburg RM, Bos AF, Derks JB; ALLO-trial study group. Behavioral and neurodevelopmental outcome of children after maternal allopurinol administration during suspected fetal hypoxia: 5-year follow up of the ALLO-trial. PLoS One. 2018 Aug 23;13(8):e0201063. doi: 10.1371/journal.pone.0201063. eCollection 2018.
Results Reference
derived
PubMed Identifier
25512466
Citation
Kaandorp JJ, Benders MJ, Schuit E, Rademaker CM, Oudijk MA, Porath MM, Oetomo SB, Wouters MG, van Elburg RM, Franssen MT, Bos AF, de Haan TR, Boon J, de Boer IP, Rijnders RJ, Jacobs CJ, Scheepers LH, Gavilanes DA, Bloemenkamp KW, Rijken M, van Meir CA, von Lindern JS, Huisjes AJ, Bakker SC, Mol BW, Visser GH, Van Bel F, Derks JB. Maternal allopurinol administration during suspected fetal hypoxia: a novel neuroprotective intervention? A multicentre randomised placebo controlled trial. Arch Dis Child Fetal Neonatal Ed. 2015 May;100(3):F216-23. doi: 10.1136/archdischild-2014-306769. Epub 2014 Dec 15.
Results Reference
derived
PubMed Identifier
24352085
Citation
Kaandorp JJ, van den Broek MP, Benders MJ, Oudijk MA, Porath MM, Bambang Oetomo S, Wouters MG, van Elburg R, Franssen MT, Bos AF, Mol BW, Visser GH, van Bel F, Rademaker CM, Derks JB; ALLO-trial Study Group. Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour. Arch Dis Child Fetal Neonatal Ed. 2014 Mar;99(2):F144-8. doi: 10.1136/archdischild-2013-304876. Epub 2013 Dec 18.
Results Reference
derived
PubMed Identifier
19564319
Citation
Torrance HL, Benders MJ, Derks JB, Rademaker CM, Bos AF, Van Den Berg P, Longini M, Buonocore G, Venegas M, Baquero H, Visser GH, Van Bel F. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. Pediatrics. 2009 Jul;124(1):350-7. doi: 10.1542/peds.2008-2228.
Results Reference
derived
Learn more about this trial
Antenatal Allopurinol During Fetal Hypoxia
We'll reach out to this number within 24 hrs